From a cellular therapeutic standpoint, Relafen 750 (Naproxen) presents an fascinating profile. This noncopyrightal drug primarily functions by inhibiting the cyclooxygenase catalysts , namely COX-1 and COX-2, which are crucial for the generation of inflammatory mediators . The subsequent lessening